Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A genetic mutation, known as GBA, that leads to early onset of Parkinson's disease and severe cognitive impairment (in about 4 to 7 percent of all patients with the disease) also alters how specific lipids, ceramides and glucosylceramides are metabolized. Mayo Clinic researchers have found that Parkinson's patients who do not carry the genetic mutation also have higher levels of these lipids in the blood. Further, those who had Parkinson's and high blood levels were also more likely to have cognitive impairment and dementia. The research was recently published online in the journal PLOS ONE.
The discovery could be an important warning for those with Parkinson's disease. Parkinson's is the second most common neurodegenerative disease after Alzheimer's disease. There is no biomarker to tell who is going to develop the disease - and who is going to develop cognitive impairment after developing Parkinson's, says Michelle Mielke, Ph.D., a Mayo Clinic researcher and first author of the study.
Cognitive impairment is a frequent symptom in Parkinson's disease and can be even more debilitating for patients and their caregivers than the characteristic motor symptoms. The early identification of Parkinson's patients at greatest risk of developing dementia is important for preventing or delaying the onset and progression of cognitive symptoms. Changing these blood lipids could be a way to stop the progression of the disease, says Dr. Mielke.
There is a suggestion this blood lipid marker also could help to predict who will develop Parkinson's disease and this research is ongoing.
"There is currently no cure for Parkinson's, but the earlier we catch it - the better chance we have to fight it," says Dr. Mielke. "It's particularly important we find a biomarker and identify it in the preclinical phase of the disease, before the onset even begins."
Dr. Mielke's lab is researching blood-based biomarkers for Parkinson's disease because blood tests are less invasive and cheaper than a brain scan or spinal tap - other tools used to research the disease.
This work was supported by grants from the National Institute on Aging (U01 AG37526) and from George P. Mitchell and the late Cynthia W. Mitchell. The DEMPARK study was being funded by an unrestricted grant from Novartis and a grant from the International Parkinson Fonds (Deutschland) gGmbH (IPD). The continuation of the study (LANDSCAPE) is part of the Competence Network Degenerative Dementias (KNDD), which is funded by the German Federal Ministry of Education and Research (project number 01GI1008C)).
Mielke MM, Maetzler W, Haughey NJ, Bandaru VVR, Savica R, et al. (2013) Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study. PLoS ONE 8(9): e73094. doi:10.1371/journal.pone.0073094
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Parkinson's Disease category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Clinic, Mayo. "Severe cognitive decline, quicker progression among Parkinson's patients may be identified by blood biomarker." Medical News Today. MediLexicon, Intl., 22 Sep. 2013. Web.
10 Dec. 2013. <http://www.medicalnewstoday.com/releases/266355>
Clinic, M. (2013, September 22). "Severe cognitive decline, quicker progression among Parkinson's patients may be identified by blood biomarker." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/266355.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.